ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

9 Months Ended

Sep. 30, 2021

Stockholders' Equity - Schedule of Share-Based Compensation for Directors Fees

Three Months Ended September 30,
2021			2020
—			6,141

Nine Months Ended September 30,
2021			2020
3,829			25,704

Stockholders’ Equity - Schedule of Stock Option Activity

Stock option activity under all of the Company’s Plans and share-based compensatory contracts during the nine months ended September 30, 2021 is summarized below:

	Option Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾ (in thousands)
Outstanding at January 1, 2021		1,806,092		$	7.12	$	20,760
Granted		121,703			18.12
Exercised		(557,184	)		2.69
Expired / terminated		(18,500	)		20.46
Outstanding at September 30, 2021		1,352,111		$	9.75	$	15,328

⁽¹⁾

Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Stockholders’ Equity - Schedule of Common Stock Warrant Activity

Common stock warrant activity for the nine months ended September 30, 2021 was as follows:

	Warrant Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾ (in thousands)
Outstanding at January 1, 2021		3,082,987		$	3.82	$	37,379
Exercised		(2,023,190	)		3.31
Terminated		(390,390	)		7.78
Outstanding at September 30, 2021		669,407		$	2.97	$	9,895

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.